Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions
Effects of other drugs on Barzolvolimab
2 evidence topics · 2 sources
Clinical drug interaction studies
No evidence found.
Extrinsic participant-specific parameters and exposure: prurigo nodularis
Prior biologics, immunosuppressives, and oral doxepin: exclusion criteria
“Key exclusion criteria were receipt of prior biologic therapy (e.g., omalizumab, dupilumab, and ligelizumab) within the past 3 months or prior treatment with barzolvolimab; treatment with immunosuppressives within 4 weeks/5 half‐lives; treatment with doxepin (oral) within 4 weeks prior to study treatment; and any other skin disease associated with chronic itching that might confound study evaluations and results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote